Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has signed a non-exclusive license with Randox Laboratories for use of its stroke protein biomarker portfolio.

Randox will use the markers in products for early diagnosis of stroke and subsequent patient monitoring. The agreement provides Proteome Sciences with "seven-digit (US dollar) license and development milestones" as well as double-digit royalties on sales, the London, UK-based company said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.